March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate ...

During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory ...

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an analysis of GMAB stock now.

T-cell therapy could potentially be moved to earlier lines of treatment in relapsed/refractory multiple myeloma based on emerging trial data, improving outcomes through earlier intervention before ...

Coeptis Inc. (Nasdaq: COEP) has taken a bold step forward in the fight against cancer by securing exclusive worldwide development and commercialization rights to the groundbreakin ...

Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...

Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...